Concepedia

Mario I. Vega

MI

Statistics

Publications

42

Citations

2.5K

H-Index

30

Active since

1982

Affiliations

University of California, Los Angeles(Current)

Hospital Infantil de México Federico Gómez

Centro Medico Nacional Siglo XXI

UCLA Jonsson Comprehensive Cancer Center

Mexican Social Security Institute

Mario I. Vega is an author at University of California, Los Angeles specializing in oncology, life sciences, and medicine.

ORCID

Publications per year

1982–2023

42

Publications

42

Inhibition of the Raf–MEK1/2–ERK1/2 Signaling Pathway, Bcl-xL Down-Regulation, and Chemosensitization of Non-Hodgkin’s Lymphoma B Cells by Rituximab

Ali R. Jazirehi, Mario I. Vega, Devasis Chatterjee et al. · Cancer Research · 2004 · 188 citations

, , +17

Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF-κB and inhibition of Bcl-xL expression

Sara Huerta‐Yépez, Mario I. Vega, Ali R. Jazirehi et al. · Oncogene · 2004 · 164 citations

, , +17

Development of Rituximab-Resistant Lymphoma Clones with Altered Cell Signaling and Cross-Resistance to Chemotherapy

Ali R. Jazirehi, Mario I. Vega, Benjamin Bonavida · Cancer Research · 2007 · 162 citations · Full text

, , +17

Global Variations in Heart Failure Etiology, Management, and Outcomes

Mariela Rasmussen, Aldo Prado, Miguel Hominal et al. · JAMA · 2023 · 157 citations · Full text

, , +17

Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: Pivotal role of p38 MAPK in drug resistance

Mario I. Vega, Sara Huerta-Yepaz, Hermes Garbán et al. · Oncogene · 2004 · 140 citations

, , +12

1–5 of 42